Form D · Biotechnology
Cognigenics, Inc.
Eagle, ID · CIK 0001940809
Offering snapshot reported Aug 17, 2022 · SEC filing
- Reported sold
- $1.59M Offering amount: $1.59M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $442K Reported outside-investor minimum
- First sale
- Jun 13, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 17, 2022 | Initial | $1,588,889 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-456119
Upon the issuer's receipt of $1,500,000 in gross proceeds from the offering, certain convertible notes of the issuer will convert into the equity being offered. The amount of principal and interest being converted is not reflected in the amounts above.
Source: Form D, filed Aug 17, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Barry Linder | Director, Executive, Promoter |
| John Mee | Director, Executive, Promoter |
| Dean Radin | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1372 South Eagle Road Suite 197
Eagle, ID, 83616
Eagle, ID, 83616